J D Lin1, K J Lin, T C Chao, C Hseuh, N M Tsang, B Y Huang. 1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, 5 Fu-Shin St Kweishan county, Taoyuan Hsien, Taiwan, Republic of China. einjd@adm.cgmh.org.tw
Abstract
BACKGROUND: In thyroid cancer patients with multiple primary cancers, primary cancers tend to be more aggressive. AIMS: We analyzed multiple primary cancers in thyroid cancer patients and determined the differences between the incidence and the characteristics of primary cancers. MATERIALS AND METHODS: A total of 3070 patients with thyroid cancer underwent a thyroidectomy and follow-up examination at a single medical center. The times of diagnosis of the primary cancers were categorized as antecedent, synchronous, or subsequent to the diagnosis of thyroid cancer. RESULTS: After a mean follow-up period of 8.8 ± 0.5 yr, the presence of multiple primary cancers was histopathologically confirmed in 163 patients (5.3%). Patients with multiple primary cancers had a lower female-to-male ratio, an older mean age, advanced tumor-node-metastasis (TNM) stage, higher total mortality, and higher therapeutic radioactive iodide (131I) doses than patients without multiple primary cancers. Hematological malignancy and renal cell carcinoma, neither of which are among the 10 most common cancers observed in the general population of Taiwan, were the most common multiple cancers among women and men with thyroid cancer. Patient age, thyroid cancer tumor size, and thyroid cancer mortality in the antecedent, synchronous, and subsequent groups were not significantly different. CONCLUSIONS: Patients with multiple primary cancers in advanced stages had shorter disease-free survival period after treatment. Thyroid cancer patients with multiple primary cancers should be closely followed up for the occurrence of other secondary cancers in order to improve total mortality.
BACKGROUND: In thyroid cancerpatients with multiple primary cancers, primary cancers tend to be more aggressive. AIMS: We analyzed multiple primary cancers in thyroid cancerpatients and determined the differences between the incidence and the characteristics of primary cancers. MATERIALS AND METHODS: A total of 3070 patients with thyroid cancer underwent a thyroidectomy and follow-up examination at a single medical center. The times of diagnosis of the primary cancers were categorized as antecedent, synchronous, or subsequent to the diagnosis of thyroid cancer. RESULTS: After a mean follow-up period of 8.8 ± 0.5 yr, the presence of multiple primary cancers was histopathologically confirmed in 163 patients (5.3%). Patients with multiple primary cancers had a lower female-to-male ratio, an older mean age, advanced tumor-node-metastasis (TNM) stage, higher total mortality, and higher therapeutic radioactive iodide (131I) doses than patients without multiple primary cancers. Hematological malignancy and renal cell carcinoma, neither of which are among the 10 most common cancers observed in the general population of Taiwan, were the most common multiple cancers among women and men with thyroid cancer. Patient age, thyroid cancer tumor size, and thyroid cancer mortality in the antecedent, synchronous, and subsequent groups were not significantly different. CONCLUSIONS:Patients with multiple primary cancers in advanced stages had shorter disease-free survival period after treatment. Thyroid cancerpatients with multiple primary cancers should be closely followed up for the occurrence of other secondary cancers in order to improve total mortality.
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Shu-Chun Chuang; Mia Hashibe; Ghislaine Scelo; David H Brewster; Eero Pukkala; Soren Friis; Elizabeth Tracey; Elisabete Weiderpass; Kari Hemminki; Sharon Tamaro; Kee-Seng Chia; Vera Pompe-Kirn; Erich V Kliewer; Jon M Tonita; Carmen Martos; Jon G Jonasson; Carolyn M Dresler; Paolo Boffetta; Paul Brennan Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-06 Impact factor: 4.254
Authors: F de Vathaire; M Schlumberger; M J Delisle; C Francese; C Challeton; E de la Genardiére; F Meunier; C Parmentier; C Hill; H Sancho-Garnier Journal: Br J Cancer Date: 1997 Impact factor: 7.640
Authors: C Rubino; F de Vathaire; M E Dottorini; P Hall; C Schvartz; J E Couette; M G Dondon; M T Abbas; C Langlois; M Schlumberger Journal: Br J Cancer Date: 2003-11-03 Impact factor: 7.640